| Xiaochuan Guo, MD, PHD | |
|
300 Seaside Ave, Milford, CT 06460-4603 | |
| (203) 876-4000 | |
| (866) 465-4714 |
| Full Name | Xiaochuan Guo |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 19 Years |
| Location | 300 Seaside Ave, Milford, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457595332 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 053218 (Connecticut) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Barnabas Health Multispecialty | 0042441891 | 20 |
| Gastroenterology Associates Of New Jersey Llc | 4284706656 | 65 |
| Vivian K Bethala Md Pa | 6800884040 | 6 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.
Waistlines are expanding at such an alarming rate across the globe that, if trends hold, almost 58 percent of the world's population will be overweight or obese by 2030, according to researchers at the Tulane School of Public Health and Tropical Medicine.
Scottsdale-based CyMedica Orthopedics, Inc. announced the commercial launch of the CyMedica QB1 System for the treatment of quadriceps muscle atrophy at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine annual meeting in Los Angeles last week.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
› Verified 5 days ago
| Entity Name | Hackensack Gastroenterology Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750459467 PECOS PAC ID: 1355248311 Enrollment ID: O20031217000613 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.
Waistlines are expanding at such an alarming rate across the globe that, if trends hold, almost 58 percent of the world's population will be overweight or obese by 2030, according to researchers at the Tulane School of Public Health and Tropical Medicine.
Scottsdale-based CyMedica Orthopedics, Inc. announced the commercial launch of the CyMedica QB1 System for the treatment of quadriceps muscle atrophy at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine annual meeting in Los Angeles last week.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
› Verified 5 days ago
| Entity Name | Advanced Ambulatory Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063415990 PECOS PAC ID: 9335134170 Enrollment ID: O20040420000134 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.
Waistlines are expanding at such an alarming rate across the globe that, if trends hold, almost 58 percent of the world's population will be overweight or obese by 2030, according to researchers at the Tulane School of Public Health and Tropical Medicine.
Scottsdale-based CyMedica Orthopedics, Inc. announced the commercial launch of the CyMedica QB1 System for the treatment of quadriceps muscle atrophy at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine annual meeting in Los Angeles last week.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
› Verified 5 days ago
| Entity Name | Heart & Vascular Associates Of Northern Jersey, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699889980 PECOS PAC ID: 4183610520 Enrollment ID: O20040422000058 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.
Waistlines are expanding at such an alarming rate across the globe that, if trends hold, almost 58 percent of the world's population will be overweight or obese by 2030, according to researchers at the Tulane School of Public Health and Tropical Medicine.
Scottsdale-based CyMedica Orthopedics, Inc. announced the commercial launch of the CyMedica QB1 System for the treatment of quadriceps muscle atrophy at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine annual meeting in Los Angeles last week.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
› Verified 5 days ago
| Entity Name | Vivian K Bethala Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568412799 PECOS PAC ID: 6800884040 Enrollment ID: O20040505000630 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.
Waistlines are expanding at such an alarming rate across the globe that, if trends hold, almost 58 percent of the world's population will be overweight or obese by 2030, according to researchers at the Tulane School of Public Health and Tropical Medicine.
Scottsdale-based CyMedica Orthopedics, Inc. announced the commercial launch of the CyMedica QB1 System for the treatment of quadriceps muscle atrophy at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine annual meeting in Los Angeles last week.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
› Verified 5 days ago
| Entity Name | Simon Kahn Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962423145 PECOS PAC ID: 6709889819 Enrollment ID: O20060810000203 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.
Waistlines are expanding at such an alarming rate across the globe that, if trends hold, almost 58 percent of the world's population will be overweight or obese by 2030, according to researchers at the Tulane School of Public Health and Tropical Medicine.
Scottsdale-based CyMedica Orthopedics, Inc. announced the commercial launch of the CyMedica QB1 System for the treatment of quadriceps muscle atrophy at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine annual meeting in Los Angeles last week.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
› Verified 5 days ago
| Entity Name | Gastroenterology Associates Of New Jersey Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497932271 PECOS PAC ID: 4284706656 Enrollment ID: O20081007000052 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.
Waistlines are expanding at such an alarming rate across the globe that, if trends hold, almost 58 percent of the world's population will be overweight or obese by 2030, according to researchers at the Tulane School of Public Health and Tropical Medicine.
Scottsdale-based CyMedica Orthopedics, Inc. announced the commercial launch of the CyMedica QB1 System for the treatment of quadriceps muscle atrophy at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine annual meeting in Los Angeles last week.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
› Verified 5 days ago
| Entity Name | Barnabas Health Multispecialty |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538597745 PECOS PAC ID: 0042441891 Enrollment ID: O20140320001524 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.
Waistlines are expanding at such an alarming rate across the globe that, if trends hold, almost 58 percent of the world's population will be overweight or obese by 2030, according to researchers at the Tulane School of Public Health and Tropical Medicine.
Scottsdale-based CyMedica Orthopedics, Inc. announced the commercial launch of the CyMedica QB1 System for the treatment of quadriceps muscle atrophy at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine annual meeting in Los Angeles last week.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Xiaochuan Guo, MD, PHD Po Box 417297, Boston, MA 02241-7297 Ph: (866) 623-3869 | Xiaochuan Guo, MD, PHD 300 Seaside Ave, Milford, CT 06460-4603 Ph: (203) 876-4000 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.
Waistlines are expanding at such an alarming rate across the globe that, if trends hold, almost 58 percent of the world's population will be overweight or obese by 2030, according to researchers at the Tulane School of Public Health and Tropical Medicine.
Scottsdale-based CyMedica Orthopedics, Inc. announced the commercial launch of the CyMedica QB1 System for the treatment of quadriceps muscle atrophy at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine annual meeting in Los Angeles last week.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
› Verified 5 days ago
Grace K Moy, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 309 Seaside Ave, Suite 201, Milford, CT 06460 Phone: 203-783-1831 Fax: 203-874-5209 | |
Dr. Kalvin Block, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 300 Seaside Ave, Milford, CT 06460 Phone: 203-876-1478 | |
Dr. Lawrence Shinbaum, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 300 Seaside Ave, Milford, CT 06460 Phone: 203-876-4178 | |
Dr. Keith Lipsitz, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 831 Boston Post Rd, Suite 203, Milford, CT 06460 Phone: 203-783-1831 | |
Dr. Hongjie Li, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 300 Seaside Ave, Milford, CT 06460 Phone: 203-876-4000 Fax: 215-957-2875 | |
Dr. Charlotte Bell, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 12 Norwood Ave, Milford, CT 06460 Phone: 203-877-8515 Fax: 203-877-8515 |